Patients with atrial fibrillation and common exclusion criteria from clinical trials are at high risk of clinical events: the Murcia AF Project II (MAFP-II) cohort study
Internal and Emergency Medicine · 2024
DOI: 10.1007/s11739-024-03701-9 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Internal and Emergency Medicine, 2024. Verfasst von Eva Soler-Espejo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital Clínico Universitario Virgen de La Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitari…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature, Universidad de Murcia.
Abstract (Originalsprache)
Background
Some clinical characteristics and comorbidities in atrial fibrillation (AF) patients are exclusion criteria in randomized clinical trials (RCTs) investigating oral anticoagulants (OAC). However, these conditions are present also in everyday clinical practice patients. We compared the risk of adverse clinical outcomes between patients with and without RCT exclusion criteria.
Methods
The Murcia AF Project II was an observational cohort study including AF outpatients starting vitamin K antagonists (VKAs) from July 2016 to June 2018. For the selection of the exclusion criteria, the four pivotal RCTs of direct-acting OAC (DOACs) were used as reference. During 2 years, all ischemic strokes/transient ischemic attacks, major adverse cardiovascular events (MACEs), major bleeds, and all-cause deaths were recorded.
Results
1050 patients (51.5% female, median age 77 years) were included, of whom 368 (35%) met at least one exclusion criterion for RCTs. During follow-up, the incidence rate ratios for major bleeding, MACE and all-cause mortality were higher among patients with exclusion criteria (all p < 0.001). Patients fulfilling at least one exclusion criterion had increased risks of major bleeding (aHR 1.48; 95% CI 1.22–1.81; p < 0.001), MACE (aHR 1.51, 95% CI 1.10–2.09, p = 0.012), and mortality (aHR 3.22, 95% CI 2.32–4.48, p < 0.001), as well as a lower event-free survival (all log-rank p < 0.001).
Conclusions
In this AF cohort taking VKAs, more than one-third had at least one RCT exclusion criteria, which translates into higher risk of major bleeding, MACE, and death. These observations should be considered when translating RCTs results to AF patients for a proper and a more patient-centered management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Hospital Clínico Universitario Virgen de La Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.
- Faculty of Nursing, University of Murcia, Murcia, Spain. josemiguel.rivera@um.es.
- Liverpool Centre of Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK. josemiguel.rivera@um.es.
- Faculty of Medicine, University of Murcia, Murcia, Spain.
- Department of Cardiology, Hospital Clínico Universitario Virgen de La Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain.
- Liverpool Centre of Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
ORCID-Profile: José Miguel Rivera-Caravaca
Förderung
- Instituto de Salud Carlos III
- Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature
- Universidad de Murcia
Zitieren
APA
Soler-Espejo, E., Rivera-Caravaca, J. M., Bru-Cánovas, J. D., Esteve-Pastor, M. A., Lip, G. Y. H., Marín, F., & Roldán, V. (2024). Patients with atrial fibrillation and common exclusion criteria from clinical trials are at high risk of clinical events: the Murcia AF Project II (MAFP-II) cohort study. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-024-03701-9
Vancouver
Soler-Espejo E, Rivera-Caravaca JM, Bru-Cánovas JD, Esteve-Pastor MA, Lip GYH, Marín F, et al. Patients with atrial fibrillation and common exclusion criteria from clinical trials are at high risk of clinical events: the Murcia AF Project II (MAFP-II) cohort study. Internal and Emergency Medicine. 2024. doi:10.1007/s11739-024-03701-9
BibTeX
@article{SolerEspejo2024,
author = {Soler-Espejo, Eva and Rivera-Caravaca, José Miguel and Bru-Cánovas, José Daniel and Esteve-Pastor, María Asunción and Lip, Gregory Yoke Hong and Marín, Francisco and Roldán, Vanessa},
title = {Patients with atrial fibrillation and common exclusion criteria from clinical trials are at high risk of clinical events: the Murcia AF Project II (MAFP-II) cohort study},
journal = {Internal and Emergency Medicine},
year = {2024},
doi = {10.1007/s11739-024-03701-9}
}
EUVIMED